PharmAthene and Altimmune announce merger

19 January 2017
mergers-acquisitions-big

US biodefense drug specialist PharmAthene (NYSE MKT: PIP) and Altimmune, a privately-held immunotherapeutics company targeting infectious diseases, have signed a definitive agreement for their merger in an all-stock transaction.

Financial terms of the transaction have not been disclosed but the news saw PharmAthene’s shares edge 1.47% to $3.45, giving it a market capitalization of around $215.5 million.

The combined company will be a fully-integrated and diversified immunotherapeutics company with four clinical stage and one preclinical stage programs. The proposed transaction does not affect PharmAthene's previously-announced special one-time cash dividend of $2.91 per share of common stock.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical